U.S. 5th Circuit appellate panel extends stay of Biden workplace vaccine requirement

A three-judge panel of the Louisiana-based U.S. 5th Circuit Court of Appeals on Friday extended its stay of the Biden administration's workplace vaccine rule, saying the groups challenging the requirement "show a great likelihood of success on the merits." The emergency workplace safety rule would require companies with 100 or more employees to ensure that their workers either be vaccinated against COVID-19 or masked and tested weekly, starting in January.
"A stay is firmly in the public interest," wrote Judge Kurt Engelhardt, an appointee of former President Donald Trump. "From economic uncertainty to workplace strife, the mere specter of the Mandate has contributed to untold economic upheaval in recent months." He said the rule, from the Labor Department's Occupational Safety and Health Administration (OSHA), "grossly exceeds OSHA's statutory authority," imposes an undue financial burden on companies, and may violate the Commerce Clause. His opinion was joined by Judges Stuart Kyle Duncan, also a Trump appointee, and Edith Jones, put on the court by former President Ronald Reagan.
The Biden administration told the court earlier this week it believes the rule is well within OSHA's authority and a stay "would likely cost dozens or even hundreds of lives per day." The administration will likely request a hearing by the full 5th Circuit appellate court, considered the most conservative in the U.S., Politico reports, but the final say may come down to a different court. A lottery scheduled for next week will determine which appeals court will hear the multiple legal challenges to the rule.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
The Week Unwrapped: Why are sinkholes becoming more common?
Podcast Plus, will Saudi investment help create the "Netflix of sport"? And why has New Zealand's new tourism campaign met with a savage reception?
By The Week UK Published
-
How Poland became Europe's military power
The Explainer Warsaw has made its armed forces a priority as it looks to protect its borders and stay close to the US
By Elizabeth Carr-Ellis, The Week UK Published
-
Quiz of The Week: 15 - 21 February
Have you been paying attention to The Week's news?
By The Week Staff Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published